Detalhe da pesquisa
1.
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
Nanomedicine
; 17: 71-81, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30654182
2.
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Br J Cancer
; 119(9): 1086-1093, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30361524
3.
Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency.
Am J Pathol
; 186(11): 2803-2812, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27751443
4.
A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.
Nanomedicine
; 11(1): 155-65, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25200610
5.
Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.
Am J Pathol
; 183(5): 1446-1460, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24035511
6.
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Toxicol Appl Pharmacol
; 262(1): 1-10, 2012 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22676972
7.
A biophysical insight into the RANTES-glycosaminoglycan interaction.
Biochim Biophys Acta
; 1794(4): 577-82, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19455751
8.
Novel svVEGF isoforms from Macrovipera lebetina venom interact with neuropilins.
Biochem Biophys Res Commun
; 389(1): 10-5, 2009 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19695228
9.
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
Clin Cancer Res
; 23(15): 4190-4202, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28298546
10.
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.
Cancer Res
; 76(6): 1517-27, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26759238
11.
VEGF-A/NRP1 stimulates GIPC1 and Syx complex formation to promote RhoA activation and proliferation in skin cancer cells.
Biol Open
; 4(9): 1063-76, 2015 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26209534
12.
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).
Mol Cancer Ther
; 14(9): 2060-71, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26162690
13.
A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: support from isothermal fluorescence titrations.
Proteins
; 54(4): 768-75, 2004 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14997572
14.
Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo.
Biosci Rep
; 33(5)2013 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23919527
15.
A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.
Mol Cancer Res
; 8(8): 1063-73, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20651020
16.
Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis.
Angiogenesis
; 11(1): 31-9, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18283547
17.
Neuropilins: novel targets for anti-angiogenesis therapies.
Cell Adh Migr
; 1(2): 56-61, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-19329879
18.
Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F.
J Biol Chem
; 282(35): 25698-707, 2007 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-17595163
19.
Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo.
J Biol Chem
; 279(21): 22294-305, 2004 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-15033992